
Syneos Health (SYENS) | Financial Analysis & Statements
Syneos Health, Inc. | Large-cap | Basic Materials
Syneos Health, Inc. | Large-cap | Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.7B
Gross Profit
514.0M
30.63%
Operating Income
147.0M
8.76%
Net Income
2.0M
0.12%
EPS (Diluted)
€-0.03
Balance Sheet Metrics
Total Assets
12.1B
Total Liabilities
4.9B
Shareholders Equity
7.3B
Debt to Equity
0.67
Cash Flow Metrics
Operating Cash Flow
40.0M
Free Cash Flow
9.0M
Revenue & Profitability Trend
Syneos Health Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 6.8B | 7.1B | 8.1B | 6.0B | 5.4B |
Cost of Goods Sold | 4.6B | 4.7B | 5.5B | 4.1B | 3.8B |
Gross Profit | 2.2B | 2.4B | 2.6B | 1.9B | 1.6B |
Gross Margin % | 32.4% | 33.6% | 32.1% | 31.2% | 29.0% |
Operating Expenses | |||||
Research & Development | 342.0M | 339.0M | 312.0M | 286.0M | 253.0M |
Selling, General & Administrative | 1.0B | 817.0M | 844.0M | 705.0M | 699.0M |
Other Operating Expenses | 161.0M | - | 222.0M | 10.0M | 219.0M |
Total Operating Expenses | 1.5B | 1.2B | 1.4B | 1.0B | 1.2B |
Operating Income | 738.0M | 1.1B | 1.3B | 746.0M | 462.0M |
Operating Margin % | 10.8% | 15.7% | 16.3% | 12.4% | 8.6% |
Non-Operating Items | |||||
Interest Income | 22.0M | 81.0M | 51.0M | 8.0M | 13.0M |
Interest Expense | 131.0M | 218.0M | 133.0M | 114.0M | 192.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 352.0M | 389.0M | 966.0M | 474.0M | -1.1B |
Income Tax | 357.0M | 192.0M | 2.0M | 22.0M | 165.0M |
Effective Tax Rate % | 101.4% | 49.4% | 0.2% | 4.6% | 0.0% |
Net Income | -5.0M | 197.0M | 964.0M | 453.0M | -1.3B |
Net Margin % | -0.1% | 2.8% | 11.9% | 7.5% | -23.8% |
Key Metrics | |||||
EBITDA | 1.5B | 1.7B | 1.8B | 1.3B | 2.4B |
EPS (Basic) | €-0.05 | €1.83 | €8.97 | €4.19 | €-12.14 |
EPS (Diluted) | €-0.05 | €1.82 | €8.97 | €4.19 | €-12.14 |
Basic Shares Outstanding | 104769297 | 105834886 | 105876417 | 105876417 | 105876417 |
Diluted Shares Outstanding | 104769297 | 105834886 | 105876417 | 105876417 | 105876417 |
Income Statement Trend
Syneos Health Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 658.0M | 1.2B | 244.0M | 139.0M | 204.0M |
Short-term Investments | 81.0M | 73.0M | 53.0M | 68.0M | 64.0M |
Accounts Receivable | 948.0M | 907.0M | 1.0B | 871.0M | 651.0M |
Inventory | 1.3B | 1.2B | 1.4B | 1.1B | 799.0M |
Other Current Assets | 1.0M | 1.0M | 1.0M | -1.0M | -1.0M |
Total Current Assets | 3.3B | 3.8B | 4.7B | 4.0B | 3.3B |
Non-Current Assets | |||||
Property, Plant & Equipment | 385.0M | 333.0M | 307.0M | 289.0M | 257.0M |
Goodwill | 7.0B | 6.8B | 7.2B | 7.0B | 6.8B |
Intangible Assets | 1.6B | 1.7B | 1.8B | 1.9B | 1.9B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 138.0M | 194.0M | 90.0M | 243.0M | 120.0M |
Total Non-Current Assets | 9.1B | 9.1B | 8.9B | 8.7B | 8.1B |
Total Assets | 12.4B | 12.9B | 13.6B | 12.7B | 11.4B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.0B | 918.0M | 972.0M | 845.0M | 560.0M |
Short-term Debt | 292.0M | 124.0M | 4.0B | 3.7B | 3.7B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 115.0M | 131.0M | 212.0M | 151.0M | 140.0M |
Total Current Liabilities | 1.9B | 1.8B | 5.7B | 5.1B | 4.8B |
Non-Current Liabilities | |||||
Long-term Debt | 1.8B | 2.2B | 1.9B | 2.1B | 2.0B |
Deferred Tax Liabilities | 381.0M | 428.0M | 479.0M | 440.0M | 459.0M |
Other Non-Current Liabilities | 50.0M | 76.0M | 23.0M | 41.0M | 42.0M |
Total Non-Current Liabilities | 3.0B | 3.4B | 2.9B | 3.2B | 3.5B |
Total Liabilities | 4.9B | 5.3B | 8.7B | 8.3B | 8.3B |
Equity | |||||
Common Stock | 1.4B | 1.4B | 5.0B | 4.5B | 3.8B |
Retained Earnings | 4.8B | 5.1B | - | - | - |
Treasury Stock | 129.0M | 59.0M | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 7.5B | 7.6B | 4.9B | 4.3B | 3.1B |
Key Metrics | |||||
Total Debt | 2.1B | 2.3B | 5.9B | 5.8B | 5.7B |
Working Capital | 1.4B | 1.9B | -1.0B | -1.1B | -1.5B |
Balance Sheet Composition
Syneos Health Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -5.0M | 197.0M | 964.0M | 453.0M | -1.3B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -167.0M | 191.0M | -347.0M | -490.0M | 246.0M |
Operating Cash Flow | -46.0M | 484.0M | 755.0M | 65.0M | -845.0M |
Investing Activities | |||||
Capital Expenditures | -500.0M | -761.0M | -515.0M | -330.0M | -233.0M |
Acquisitions | 9.0M | 30.0M | 66.0M | 39.0M | 5.0M |
Investment Purchases | -3.0M | -15.0M | -3.0M | -14.0M | -46.0M |
Investment Sales | - | - | 1.0M | 0 | 0 |
Investing Cash Flow | -494.0M | -1.3B | -679.0M | -488.0M | -280.0M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -170.0M | -436.0M | -237.0M | -271.0M | -338.0M |
Debt Issuance | 1.3B | 1.8B | 426.0M | 195.0M | 278.0M |
Debt Repayment | -1.6B | -3.2B | -410.0M | -334.0M | -1.0B |
Financing Cash Flow | -449.0M | 1.1B | -420.0M | 19.0M | -484.0M |
Free Cash Flow | 217.0M | 425.0M | 745.0M | 274.0M | 775.0M |
Net Change in Cash | -989.0M | 235.0M | -344.0M | -404.0M | -1.6B |
Cash Flow Trend
Syneos Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
377.86
Forward P/E
9.65
Price to Book
1.19
Price to Sales
1.10
PEG Ratio
5.04
Profitability Ratios
Profit Margin
-1.30%
Operating Margin
10.86%
Return on Equity
-1.20%
Return on Assets
3.16%
Financial Health
Current Ratio
2.27
Debt to Equity
45.57
Per Share Data
EPS (TTM)
€-0.81
Book Value per Share
€60.47
Revenue per Share
€64.37
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
syens | 7.4B | 377.86 | 1.19 | -1.20% | -1.30% | 45.57 |
Solvay SA | 2.9B | 20.70 | 2.49 | 11.13% | 2.81% | 185.12 |
Solvac S.A | 1.9B | 18.45 | 0.77 | 4.16% | 2,518,580.00% | 5.96 |
Azelis Group NV | 3.1B | 17.67 | 1.12 | 6.41% | 4.01% | 77.22 |
Titan Cement | 2.7B | 13.11 | 1.51 | 12.28% | 7.88% | 36.26 |
Tessenderlo Group NV | 1.5B | 37.21 | 0.86 | -1.40% | -0.99% | 14.34 |
Financial data is updated regularly. All figures are in the company's reporting currency.